No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Aarti Drugs Limited, through its affiliated companies, is a key participant in the pharmaceutical and chemical sectors, focusing on the worldwide production and sale of active pharmaceutical ingredients (APIs), vital pharmaceutical intermediates, a wide variety of specialty chemicals, and finished drug formulations. The company's comprehensive range of APIs addresses numerous medical conditions, including inflammation, cardiovascular health, gastrointestinal issues, fungal infections, bone and joint health (such as arthritis and osteoporosis), bacterial infections, diabetes, Alzheimer's disease, sedation, vitamin deficiencies, and alcoholism. Among the critical pharmaceutical intermediates it supplies are compounds like tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, and raloxifene. Furthermore, Aarti Drugs manufactures an extensive portfolio of specialty chemicals, notably various benzene and toluene sulphonyl derivatives such as benzene sulphonyl chloride, sodium benzene sulfinate, para toluene sulphonyl chloride, di-phenyl sulphone, and formamide, along with many others. The company is also advancing a development pipeline that includes Itraconazole and Fluconazole for antifungal uses, Dabigatran for its anticoagulant properties, Ticagrelor for treating cardiovascular ailments, Sitagliptin for managing diabetes, and Alpha Lipoic Acid as an antioxidant. Beyond its manufacturing activities, the firm provides contract manufacturing services. Established in 1984, Aarti Drugs Limited is headquartered in Mumbai, India.
www.aartidrugs.co.inNo one on the platform currently holds AARTIDRUGS.BO.
No tracked institution reports a position in AARTIDRUGS.BO as of their last filing.
No one on the platform has traded AARTIDRUGS.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.6% | 15.1% | 14.6% | — | — | — |
| Rev. Growth % | 7.5% | 3.5% | ||||
| Profit Margin % | 7.6% | 7.2% | 7.6% | |||
| Free Cash Flow Margin % | 1.9% | 1.1% | 2.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $29.5B | +13.0% | $23.70 | $23.70–$23.70 | — | 1 |
| 2028 | $32.7B | +10.8% | $27.90 | $27.90–$27.90 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 6 of the last 7 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $5.40 | $5.40 | +0.0% |
| 2026-05-15 | $5.00 | $6.05 | +21.0% |
| 2026-02-03 | $4.90 | $4.40 | -10.2% |
| 2025-10-22 | $4.90 | $4.90 | +0.0% |
| 2025-07-18 | $4.90 | $5.90 | +20.4% |
| 2025-01-29 | $3.70 | $4.10 | +10.8% |
| 2024-10-24 | $3.90 | $3.90 | +0.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AARTIDRUGS.BOAarti Drugs Limited | $426.85 | -0.32% | $39.0B | — |
| INNOVACAP.NSInnova Captab Limited | $1140.10 | -0.62% | $65.2B | — |
| ORCHPHARMA.NSOrchid Pharma Limited | $987.00 | -1.60% | $50.1B | — |
| RPGLIFE.BORPG Life Sciences Limited | $2717.40 | +0.46% | $45.3B | — |
| RPGLIFE.NSRPG Life Sciences Limited |
| $2718.80 |
| +0.75% |
| $45.0B |
| — |
| SPARC.BOSun Pharma Advanced Research Company Limited | $188.20 | -4.03% | $60.9B | — |
| SPARC.NSSun Pharma Advanced Research Company Limited | $188.00 | -4.09% | $61.0B | — |
Source: Financial Modeling Prep · peers by sector/industry